BML-275
BML-275 Basic information
- Product Name:
- BML-275
- Synonyms:
-
- dorsoMorphin (Hydrochloride)
- DorsoMorphin, Dihydrochloride Salt, >99%
- BML-275,Compound C
- 6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine hydrochloride (1:2) Dorsomorphin 2HCl
- Dorsomorphin-2HCl BML-275
- 6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine hydrochloride (1:2)
- BML-275 dihydrochloride
- Dorsomorphin(BML-275)dihydrochloride
- CAS:
- 1219168-18-9
- MF:
- C24H27Cl2N5O
- MW:
- 472.41008
- Product Categories:
-
- PI3K/Akt/mTOR
- Inhibitors
- Akt
- mTOR
- PI3K
- Mol File:
- 1219168-18-9.mol
BML-275 Chemical Properties
- storage temp.
- under inert gas (nitrogen or Argon) at 2-8°C
- solubility
- insoluble in EtOH; insoluble in H2O; ≥11.34 mg/mL in 0.9% NS ; ≥39.93 mg/mL in DMSO:H2O=2:1 ; ≥5.91 mg/mL in DMSO
- form
- Light yellow powder solid.
- color
- Yellow
- Stability:
- Hygroscopic
BML-275 Usage And Synthesis
Description
Dorsomorphin (hydrochloride) is a potent, reversible inhibitor of AMP kinase (AMPK; Ki = 109 nM) that does not exhibit significant activity on structurally related kinases, including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin can also dose-dependently inhibit the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6). Independent of AMPK inhibition, dorsomorphin, at 10 μM, has additionally been shown to downregulate the Akt/mTOR pathway to induce autophagy in U251 human glioma cells.
Uses
Dorsomorphin is an AMP-activated kinase (AMPK) inhibitor. Dorsomorphin selectively inhibits the bone morphogenetic protein (BMP) type I receptors ALK2, ALK3 and ALK6 and thus blocks BMP-mediated SMAD1/5/8 phosphorylation, target gene transcription and osteogenic differentiation. Dorsomorphin has shown to increase cisplatin-induced apoptosis, which was associated with hyper-induction of the tumor suppressor p53.
in vivo
Dorsomorphin (compound C; 10 mg/kg, intravenously once) dihydrochloride treatment leads to a 60% increase in total serum iron concentrations, reduces basal levels of hepcidin expression and increases serum iron concentrations in adult mice[3].
Dorsomorphin (0.2 mg/kg, i.v., 30 min before LPS injection) dihydrochloride reduces ICAM-1 and VCAM-1 expression in LPS-injected rat aorta[4].
Dorsomorphin (25 mg/kg; i.p. injection, in male BALB/c mice) dihydrochloride treatment before lipopolysaccharide (LPS) injection significantly reduces lethality in contrast to animals treated with LPS challenge only[5].
| Animal Model: | Wild-type (WT) C57BL/6 adult mice that are fed a standard iron-replete diet express high levels of hepcidin[3]. |
| Dosage: | 10 mg/kg. |
| Administration: | Intravenously once. |
| Result: | Led to a 60% increase in total serum iron concentrations. Effective in reducing basal levels of hepcidin expression and increasing serum iron concentrations in adult mice. |
| Animal Model: | Male Sprague-Dawley rats, 8 weeks of age (body weight 230-250 g)[4]. |
| Dosage: | 0.2 mg/kg. |
| Administration: | I.V., 30 min before LPS injection. |
| Result: | Reduced ICAM-1 and VCAM-1 expression in LPS-injected rat aorta. |
| Animal Model: | Male BALB/c mice at 6-7 weeks of age weighing 20-22 g[5] |
| Dosage: | 25 mg/kg |
| Administration: | Injection i.p.; 60 min before LPS challenge |
| Result: | Treatment of mice with 25 mg/kg before LPS injection significantly reduced lethality in contrast to animals treated with LPS challenge only. |
IC 50
AMPK: 109 nM (Ki); ACVR1; BMPR1A; ALK6; Autophagy
storage
Room temperature (desiccate)
References
[1] ZHOU G, MYERS R W, LI Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action.[J]. The Journal of clinical investigation, 2001, 1 1: 0. DOI: 10.1172/jci13505
[2] PAUL B YU. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism[J]. Nature chemical biology, 2007, 4 1: 33-41. DOI: 10.1038/nchembio.2007.54
[3] LJUBICA VUCICEVIC. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.[J]. Autophagy, 2011, 7 1: 40-50. DOI: 10.4161/auto.7.1.13883
BML-275Supplier
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 0311-85461665 13784393231
- leichemist@126.com
- Tel
- 0531-88811783
- sales@trio-pharmatech.com
BML-275(1219168-18-9)Related Product Information
- D-ERYTHRO-SPHINGOSINE
- 3-METHYLADENINE
- SB 431542
- A 769662
- AICAR
- Rapamycin
- LY 294002 Hydrochloride
- KU-55933
- Selumetinib
- PLX-4720
- CX-4945
- Fluoxetine hydrochloride
- Alpelisib (BYL719)
- Tubastatin A hydrochloride
- N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide hydrochloride
- BI 2536
- Neratinib
- Glucagon Receptor Antagonist I